Download MendeleyDiscovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.
Marineau, J.J., Hamman, K.B., Hu, S., Alnemy, S., Mihalich, J., Kabro, A., Whitmore, K.M., Winter, D.K., Roy, S., Ciblat, S., Ke, N., Savinainen, A., Wilsily, A., Malojcic, G., Zahler, R., Schmidt, D., Bradley, M.J., Waters, N.J., Chuaqui, C.(2022) J Med Chem 65: 1458-1480
- PubMed: 34726887
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01171
- Primary Citation of Related Structures:
7RA5 - PubMed Abstract:
CDK7 has emerged as an exciting target in oncology due to its roles in two important processes that are misregulated in cancer cells: cell cycle and transcription. This report describes the discovery of SY-5609 , a highly potent (sub-nM CDK7 K d ) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126). Structure-based design was leveraged to obtain high selectivity (>4000-times the closest off target) and slow off-rate binding kinetics desirable for potent cellular activity. Finally, incorporation of a phosphine oxide as an atypical hydrogen bond acceptor helped provide the required potency and metabolic stability. The development candidate SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.
Organizational Affiliation:
Syros Pharmaceuticals Inc., 35 Cambridge Park Drive, Fourth Floor, Cambridge, Massachusetts 02140, United States.
